Best Probiotic for Men Evidence-graded, strain by strain

Probiotics for IBS in men: the trial record, strain by strain

There is no human RCT of any named probiotic strain, in men only, with an IBS, bloating or constipation symptom endpoint. ClinicalTrials.gov holds 132 IBS + probiotic studies (124 all-sex, 8 female-only, 0 male-only) and 63 functional-constipation + probiotic studies (58 all-sex, 5 female-only, 0 male-only). All counts independently reproduced on 29 July 2026.

, Independent analyst Last verified Disclosures

IBS is one of the outcomes that earns a grade on this site, so this page is where the grade is argued rather than asserted — including the guideline body that disagrees with the rest of them.

Digestion, IBS and regularity

Exactly one trial in the entire digestive-probiotic literature ran a pre-defined sex comparison, and it was null. BB-12, n=1,248 randomised / 1,000 per-protocol — the largest probiotic digestive RCT ever run. Randomisation was stratified by sex and hormonal status, so the sex subgroup was pre-defined, not post hoc. Men were 20.3–20.4% (~254). The result, verbatim: "There was no significant difference between the subgroups of sex/hormonal status (P=0·44)." Funding, verbatim: "Design, conduct, analysis and reporting of the study, as well as writing of this manuscript, were funded in full by Chr. Hansen A/S", with four employee authors (PMID 26382580).

That same trial missed both of its pre-specified primary endpoints. Defecation-frequency responder OR 1.31 (0.98–1.75), P=0.071; GI well-being not significant. The widely quoted OR 1.55 (1.22–1.96), P=0.0003 rests on a responder definition tightened after the fact, which the paper itself labels post hoc. And verbatim: "Abdominal pain and bloating decreased during the study in all the groups… but no difference between treatments was found."

The single most useful sentence in this literature comes from the AGA's own technical review: "These 55 trials tested 44 different probiotic species/strains or combinations… for the majority of probiotics, the total body of evidence is derived from a single trial" — 55 trials, 5,301 patients, overall certainty across critical IBS outcomes Low (PMID 32531292).

The honest ceiling for the whole category: 82 RCTs, 10,332 patients, only 24 at low risk of bias, and "Certainty in the evidence for efficacy by GRADE criteria was low to very low across almost all of our analyses" (PMID 37541528).

Guideline bodies rate it low, two decline to recommend it, and one is a genuine outlier that we are not going to hide. ACG 2021: "We suggest against probiotics for the treatment of global IBS symptoms. Conditional recommendation; very low level of evidence." AGA 2020: "The use of probiotics is recommended only in the context of a clinical trial" — no recommendation, very low quality. BSG 2021: weak recommendation, very low quality; take for up to 12 weeks and stop if no improvement. NICE CG61 §1.2.1.6: "People with IBS who choose to try probiotics should be advised to take the product for at least 4 weeks while monitoring the effect" — and it names no strain. JSGE 2021 is the outlier: a major post-2020 guideline body that rated the evidence HIGH with a STRONG recommendation. That disagreement is real and belongs inside the claim, not in a footnote.

More CFU is not more effect, and the cleanest demonstration is in ACG's own review. Over 300 subjects were randomised to 10⁶, 10⁸ or 10¹⁰ CFU/mL of B. infantis 35624 or placebo — improvement was reported in the 10⁸ group and not the other two, which ACG describes as "confusing because the lack of dose response was challenging to explain" (PMID 33315591). ISAPP's own position matches: "A greater number of colony forming units (CFU) does not always equate with enhanced effects… Most probiotics have been tested at levels between 1-10 billion CFU/d."

The most-marketed IBS strain's pivotal trial enrolled no men at all. B. longum subsp. longum 35624, n=362 — the title reads "…in women with irritable bowel syndrome", and only the 1×10⁸ dose beat placebo (PMID 16863564). The only general-population trial of that strain failed its primary endpoint: 302 randomised / 275 evaluable, 79% female, 10 US centres, and "no significant differences between the probiotic and the placebo groups in either abdominal discomfort or bloating (P>0.3)" (PMID 27845337).

A probiotic can also make IBS worse. L. plantarum MF1298 — the best of 22 lactobacilli screened in vitro — made symptoms significantly worse: 13 of 16 (81%, 95% CI 57–93%, P=0.012) preferred placebo; IBS sum score 6.44 versus 5.35 (P=0.010); number needed to harm 3.7 (95% CI 2.3–10.9) (PMID 20144246).

On regularity, the strain marketed hardest for it has the weakest case. B. animalis subsp. lactis HN019 has zero IBS trials ("HN019" AND "irritable bowel" = 0 records, re-verified 29 July 2026), and both larger constipation trials failed: "There were no statistically significant differences in the primary or secondary outcomes between interventions" (n=228, author at DuPont, the manufacturer; PMID 29227175) and "HN019 was not found to be superior in managing FC compared to placebo… This study did not support the expected effect of HN019 on improving CSBM frequency" (authors at International Flavors & Fragrances; PMID 40320938). The one positive result is a 14-day whole-gut-transit-time surrogate, funded by the Fonterra Research Centre with capsules supplied by Danisco USA, in a paper stating "The authors report no conflicts of interest" (PMID 21663486).

Where these outcomes sit in the 22-row table

The grade is assigned on the hub’s 22-row table and argued above. The row s are reproduced here unchanged, so the grade a reader quotes from this page is the same grade the table carries. What a grade measures is set out under how the grades work: it is a statement about the strength of the evidence for a named strain, never a statement that a product does anything.

The rows of the 22-row outcome table this page is the long version of. Default order: as numbered in the full table. Sortable columns are marked; sorting needs JavaScript, the order above does not.
# Outcome Best grade at strain level The strain, and the trial behind it Buyable at the dose that was studied?
3 IBS pain and bloating (diagnosed IBS) Lactiplantibacillus plantarum 299v (DSM 9843); Bacillus coagulans Unique IS2 (MTCC 5260) Partly — 299v sits in one product inside a proprietary blend, so its dose is unknowable; Unique IS2 is in none
12 Regularity and constipation Class-level only; the strain marketed hardest for "regularity" failed both of its clinical-endpoint trials N/A

The strains named above, and the labels in this audit that print them

Every row below is a line on a printed supplement panel, read off that product’s own teardown. A panel printing a designator is a fact about the panel. It is not evidence that the product was tested, that it delivers the amount that was studied, or that the strain does anything — several of the paragraphs above say in terms that it does not, and the dose is unknowable wherever the panel gives no per-organism quantity.

L. plantarum 299v (DSM 9843)
B. coagulans Unique IS2 (MTCC 5260)
B. longum subsp. longum 35624
B. animalis subsp. lactis HN019
L. rhamnosus GG (ATCC 53103)
BB-12
L. plantarum MF1298

Not printed on any panel this audit has transcribed.

Scope, stated because an absence here is a published claim: this searches the organism slots transcribed from 156 of the 166 labels in the audit. A panel that is not fully transcribed can hide a line, so “not printed on any panel this audit has transcribed” is exactly that, and never “not sold anywhere”. Each product links to its own label audit, where the panel, the designator resolution and the arithmetic are set out in full.

Read next

This is the section published on the home page under #digestion, relocated unchanged.